Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial

Ozelo M 1 , Misgav M 2 , Abdul Karim F 3 , Lentz SR 4 , Martin-Salces M 5 , Matytsina I 6 Show all authors , Saugstrup T 6 , Santagostino E 7

Affiliations 

  • 1 IHTC 'Claudio L.P. Correa', INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, Brazil
  • 2 National Hemophilia Center, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
  • 3 National Blood Centre, Kuala Lumpur, Malaysia
  • 4 The University of Iowa Carver College of Medicine, Iowa City, IA, USA
  • 5 Haematology Department, Hospital Universitario La Paz, Madrid, Spain
  • 6 Novo Nordisk A/S, Soeborg, Denmark
  • 7 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital Policlinico, Milan, Italy
Haemophilia, 2015 Sep;21(5):e436-9.
PMID: 26058730 DOI: 10.1111/hae.12737

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications